View Older Stories View More Recent Stories

Jun 1, 2021 08:30AM Myovant Sciences to Present at Upcoming Investor Conferences
May 26, 2021 04:15PM Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
May 26, 2021 04:15PM Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
May 26, 2021 08:00AM Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical Development and Corporate Achievements Across its Portfolio of Companies
May 21, 2021 08:30AM Myovant Sciences (MYOV) Receives Positive CHMP Opinion for RYEQO for Treatment of Women With Uterine Fibroids
May 21, 2021 08:30AM Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
May 21, 2021 08:30AM Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
May 11, 2021 06:58AM Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021
May 4, 2021 08:30AM Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on May 11, 2021
May 4, 2021 08:30AM Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on May 11, 2021
Apr 12, 2021 06:58AM Myovant Sciences (MYOV), Pfizer (PFE) Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
Apr 12, 2021 06:58AM Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
Apr 12, 2021 06:58AM Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
Apr 5, 2021 06:59AM Myovant Sciences (MYOV) Appoints Lauren Merendino as Chief Commercial Officer
Apr 5, 2021 06:58AM Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
Apr 5, 2021 06:58AM Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
Mar 29, 2021 06:59AM Myovant Sciences (MYOV) Granted EMA Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
Mar 29, 2021 06:58AM Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
Mar 29, 2021 06:58AM Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
Mar 24, 2021 06:30AM Myovant Sciences (MYOV), Pfizer (PFE) Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Mar 24, 2021 06:30AM Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Mar 24, 2021 06:30AM Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Mar 23, 2021 08:30AM Myovant Sciences Announces Recipients of “Forward for Health Equity” Grants to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
Mar 23, 2021 08:30AM Myovant Sciences Announces Recipients of “Forward for Health Equity” Grants to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
Feb 22, 2021 08:30AM Myovant Sciences to Present at Upcoming Investor Conferences
Feb 22, 2021 08:30AM Myovant Sciences to Present at Upcoming Investor Conferences
Feb 17, 2021 08:02PM Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Feb 17, 2021 05:04PM Myovant Sciences (MYOV), Pfizer (PFE) Announce Publication in NEJM of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Feb 17, 2021 05:02PM Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Feb 17, 2021 05:02PM Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Feb 17, 2021 08:30AM Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Feb 16, 2021 08:32AM HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
Feb 11, 2021 06:55AM Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2020
Jan 29, 2021 08:30AM Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021
Jan 29, 2021 08:30AM Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021
Jan 26, 2021 05:27PM UPDATE: Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Jan 26, 2021 02:28PM Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Jan 26, 2021 06:58AM Myovant Sciences (MYOV) , Pfizer (PFE) Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Jan 26, 2021 06:55AM Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Jan 26, 2021 06:55AM Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Jan 20, 2021 08:30AM Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Jan 5, 2021 02:56PM CORRECTION -- Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
Jan 5, 2021 02:56PM CORRECTION -- Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
Jan 5, 2021 08:30AM Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
Jan 5, 2021 08:30AM Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
Jan 5, 2021 06:58AM Myovant Sciences (MYOV) Announces U.S. Availability of ORGOVYX for Treatment of Advanced Prostate Cancer
Jan 5, 2021 06:58AM Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
Jan 5, 2021 06:58AM Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
Jan 4, 2021 07:10AM SUMITOVANT BIOPHARMA ANNOUNCES THE APPOINTMENT OF INDUSTRY VETERAN, DAVID MAREK, AS CHIEF EXECUTIVE OFFICER OF MYOVANT SCIENCES
Jan 4, 2021 06:58AM Myovant Sciences (MYOV) Appoints David Marek as Chief Executive Officer
View More Recent Stories View Older Stories